Study of Oral MRT-2359 in Selected Cancer Patients

This Phase 1/2, open-label, multicenter, dose escalation and expansion study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary clinical activity of MRT-2359 in patients with previously treated selected solid tumors, including lung cancer (NSCLC and SCLC), high-grade neuroendocrine cancer of any primary site, and DLBCL. * The primary aim of Phase 1 part is safety, tolerability, MTD and/or RP2D of MRT-2359. * The primary aim of Phase 2 part is assessment of preliminary anti-tumor activity of MRT-2359.